Study: Wearing Hearing Aids Before 70 Cuts Dementia Risk by 61% – What You Need to Know

If you or someone you know has been putting off addressing hearing loss, new research gives a compelling reason to reconsider. A study tracking nearly 3,000 adults for up to two decades found that the timing of hearing aid use, specifically whether it begins before age 70, is associated with a dramatic reduction in dementia risk. The 61% figure is not a projection or a model. It reflects actual dementia outcomes tracked over decades in real patients.

This article breaks down what the research found, why the age threshold matters, what is happening in the brain to explain the connection, and what the findings mean practically for anyone with hearing loss or caring for someone who has it. We also cover the latest development in hearing technology for children, a new AI-powered earmold system from Western University that is changing how pediatric hearing care is delivered in 2026.

The Study: What Researchers Found

The research, published in JAMA Neurology on August 18, 2025, analyzed data from 2,953 adults aged 60 and older who were enrolled in the Framingham Heart Study, one of the longest-running cardiovascular and neurological studies in American medical history. Participants had undergone audiometric testing between the late 1970s and late 1990s and were followed for incident dementia for up to 20 years after baseline.

Among participants who were younger than 70 at the time of their hearing assessment and who had documented hearing loss (defined as an average threshold of 26 decibels or higher in the better ear), those who reported using hearing aids developed dementia at significantly lower rates than those who did not. The risk reduction measured 61%, a statistically robust finding given the sample size and the duration of follow-up.

The lead authors, including Lily Francis and senior author Sudha Seshadri of the Framingham Heart Study team, were careful to note the study’s observational design. Because participants self-reported hearing aid use, the researchers could not assess consistency of use, hours worn per day, or device quality. The study also cannot establish causation in the strict experimental sense. What it adds is a large-scale, long-duration data point that aligns with the direction of multiple prior studies.

Of the 2,953 participants in the analysis, 583 went on to develop dementia over the follow-up period, representing 20% of the cohort. This prevalence figure underscores why the question of modifiable risk factors matters: one in five older adults in this well-studied population developed dementia, and hearing aid use was one of the variables most strongly associated with not being in that group.

Research published in JAMA Neurology found that adults who begin using hearing aids before age 70 have a 61% lower risk of developing dementia. Starting earlier appears to matter more than most people realize.

Why the Under-70 Finding Is the Most Important Part

The study’s most actionable finding is not simply that hearing aids help, but that the benefit appears to be concentrated in people who begin using them before age 70. In participants who were 70 or older at the time of their hearing assessment, the protective association with hearing aid use disappeared entirely. The researchers could not definitively determine whether this age boundary reflects a difference in intervention timing, a difference in baseline hearing loss severity between the two groups, or some other biological factor.

What it suggests clinically is that there may be a window during which hearing intervention can meaningfully interrupt the cognitive processes associated with dementia risk, and that window may close around or before age 70. This is consistent with broader neuroscience research on cognitive reserve, which holds that interventions to maintain sensory input and cognitive engagement are more effective when the brain retains greater plasticity and reserve capacity.

The practical implication is significant. Adults who notice hearing difficulties in their 50s or early 60s and delay evaluation or treatment may be passing through a period when early action carries disproportionate long-term benefit. The Lancet Commission on Dementia Prevention, which in 2024 identified hearing loss as one of 14 modifiable risk factors for dementia, has similarly highlighted midlife hearing loss as a particularly important intervention target.

How Hearing Loss May Contribute to Dementia Risk

Researchers have proposed several mechanisms to explain why untreated hearing loss is associated with accelerated cognitive decline. None is considered definitive on its own, and the relationship is likely multifactorial:

• Cognitive load theory: When the auditory system cannot resolve speech clearly, the brain must recruit additional processing resources to interpret degraded sound signals. Over years and decades, this sustained increase in cognitive demand may exhaust neural resources and accelerate decline in other cognitive domains including memory and executive function.
• Social isolation and reduced stimulation: People with untreated hearing loss disproportionately withdraw from conversations, social gatherings, and complex auditory environments. Social isolation is independently associated with increased dementia risk, and the combination of reduced sensory input and reduced social engagement may compound the effect.
• Shared pathological cause: Some researchers argue that the observed correlation is partly explained by shared underlying causes. Vascular damage and systemic inflammation, for instance, contribute to both cochlear degeneration and neurodegeneration. On this view, hearing loss and dementia may share common roots rather than one causing the other. The Framingham study team acknowledged this possibility as a limitation.
• Brain structure changes: Neuroimaging studies have documented accelerated gray matter loss and reduced auditory cortex volume in adults with untreated hearing loss compared to those with corrected hearing. Whether hearing aids slow this structural deterioration directly is an area of ongoing investigation.

The ACHIEVE Trial, a randomized controlled study funded by the National Institutes of Health and published in The Lancet, found that hearing intervention cut the rate of cognitive decline by nearly 50% in older adults identified as being at high risk for dementia. While ACHIEVE focused on adults 70 to 84, its randomized design provides stronger evidence of a causal link than observational studies alone can offer.

Western University’s ALLEars Project: AI-Powered Hearing Care for Children (April 2026)

While the dementia study addresses the urgency of hearing intervention in adults, a separate development in April 2026 signals a generational shift in how hearing technology is being designed for children. Researchers at Western University in Ontario, Canada, in collaboration with Boys Town National Research Hospital in Nebraska, announced the ALLEars project: an AI-powered system that predicts how a child’s ear will grow and 3D-prints custom earmolds in advance.

Children with hearing loss who use behind-the-ear hearing aids require custom earmolds that fit precisely to the contours of their ear canal. Because children’s ears grow rapidly in the first years of life, these molds become ill-fitting within months, creating acoustic gaps that compromise the child’s ability to receive properly calibrated sound. Under the current standard of care, families must return for new impressions every few months and then wait 14 to 21 days for replacement molds to be manufactured and delivered.

The ALLEars system, developed by Professor Soodeh Nikan’s engineering team at Western, trains AI models on large datasets of ear impressions to predict future ear growth trajectories. The system can also use the shape of one ear to estimate the shape of the other, reducing the number of impressions a child needs to undergo. Combined with a 3D printing workflow developed by Joshua Pearce’s lab at Western, the project aims to allow audiologists to produce accurately fitted replacement molds on-demand, ahead of the child’s next growth phase rather than after it has already occurred.

The project is funded by a $4.4 million, four-year grant from the Oberkotter Foundation, which supports early listening and spoken language development for deaf and hard-of-hearing children. The ALLEars project is currently in its pilot data collection phase, building the datasets needed to train and validate the predictive AI models before clinical rollout.

What the Research Means Practically for You

The convergence of the Framingham findings and the growing body of dementia-prevention research produces a clear message for adults currently experiencing hearing difficulties: getting evaluated and treated earlier rather than later matters in ways that extend well beyond hearing alone.

A standard audiological evaluation takes about an hour and can be accessed through an audiologist, an otolaryngologist (ENT), or increasingly through telehealth-compatible online hearing tests paired with over-the-counter (OTC) hearing aids. The FDA’s 2022 establishment of the OTC hearing aid category has significantly reduced the cost and accessibility barrier for adults with mild to moderate hearing loss, which is the category most studied in the dementia research.

If you have been waiting for “the right time” to address hearing loss or dismissing early symptoms as minor, the research suggests the right time is before age 70, and the earlier the better. Adults who already use hearing aids consistently should find the new data affirming. Those using them inconsistently, or who have devices they do not wear regularly, may want to revisit the question of fit, comfort, and sound quality with their provider, since the Framingham study could not measure whether occasional hearing aid use carries the same benefit as daily, consistent use.

Hearing Aid Options Worth Considering in 2026

For adults looking to act on the dementia research and for families seeking solutions for children with hearing loss, the hearing aid market in 2026 offers significantly more options at more accessible price points than were available even five years ago. Here are some of the most reviewed options in BestGuide’s hearing aid coverage:

• Lexie Hearing has built a strong reputation for OTC hearing aids that pair well with smartphone apps, making adjustment accessible for adults who want control over their settings without repeated audiology visits. Its subscription-based support model is frequently cited in reviews as a meaningful advantage over traditional one-time purchase models.
• MDHearing is among the most established names in direct-to-consumer hearing aids, with devices reviewed for their balance of affordability and clinical-grade amplification. Its telehealth audiology support option helps users get more out of their devices without requiring in-person appointments.
• Audicus focuses on custom-programmed hearing aids delivered by mail after a remote hearing test, a model that appeals to adults who prefer a more clinical fit than typical OTC options without the cost of a traditional audiologist office model.
• Ceretone has emerged as a notable option for adults prioritizing discreet, lightweight designs at accessible prices, with consistent positive feedback on comfort for all-day wear, which the dementia research suggests is the most beneficial usage pattern.
• SoundBright is a newer entrant reviewed for its emphasis on sound clarity in noisy environments, a common complaint point for hearing aid users that, when unresolved, often leads to inconsistent device use.
• Jabra Enhance (formerly Lively) brings a clinically grounded approach to OTC hearing aids, with devices supported by remote audiologist programming. For adults motivated by the dementia research who want the reassurance of a professional fitting without in-office visits, the Jabra model is a natural fit.
• Eargo stands out for its nearly invisible, rechargeable design that sits entirely inside the ear canal. For adults who have avoided hearing aids primarily because of stigma or aesthetics, Eargo removes the most common barrier to consistent daily use, which the Framingham study data suggests is where the protective benefit is concentrated.
• Starkey is the most technology-forward prescription brand in BestGuide’s coverage, with AI-powered features including fall detection, real-time translation, and adaptive noise management built into the device itself. For adults with moderate to severe hearing loss who require a prescription fitting, Starkey is the brand most aligned with the direction of research like the ALLEars project, where AI and audiology are converging.

For a comprehensive side-by-side comparison of tested brands including pricing, fit types, and battery options, see our full best hearing aids guide.

Frequently Asked Questions

Can hearing aids really reduce dementia risk?
Based on current research, yes, particularly when used before age 70. A 2025 study in JAMA Neurology found a 61% lower dementia risk in adults under 70 with hearing loss who used hearing aids compared to those with untreated loss. The NIH-funded ACHIEVE Trial found hearing intervention cut cognitive decline rates by nearly 50% in high-risk older adults. Researchers do not yet have full certainty about the exact mechanism, but the direction of evidence across multiple large studies is consistent enough that the World Health Organization identified hearing intervention as a warranted public health priority for dementia prevention.

Why does it matter whether you start hearing aids before or after age 70?
The 2025 Framingham study found the 61% risk reduction applied only to participants under 70 at the time of their hearing assessment. No significant protective effect was found in participants 70 or older. Researchers believe this may reflect a window during which hearing intervention can meaningfully protect cognitive reserve, though the exact reason for the age threshold is still being studied. The practical implication is that earlier evaluation and treatment is likely more beneficial than waiting.

What was the Framingham Heart Study hearing aid research?
The study, published in JAMA Neurology in August 2025, analyzed data from 2,953 adults aged 60 and older from the Framingham Heart Study cohort, followed for up to 20 years after audiometric testing. Among those under 70 at baseline with hearing loss, those using hearing aids had a 61% lower rate of developing dementia. Of all 2,953 participants, 583 (approximately 20%) developed dementia over the follow-up period.

What is the Western University ALLEars project?
ALLEars is an AI-powered system developed by Western University in Canada and Boys Town National Research Hospital that predicts how a child’s ear will grow and uses 3D printing to produce custom earmolds in advance of future growth. The project addresses a critical gap in pediatric hearing care: children’s ears grow rapidly, causing earmolds to become ill-fitting within months. ALLEars is funded by a $4.4 million grant from the Oberkotter Foundation and is currently in pilot data collection phase.

What type of hearing loss do these studies apply to?
The Framingham study defined hearing loss as an average audiometric threshold of 26 decibels or higher in the better ear, which spans the range from mild to more significant hearing loss. The majority of adults in the study had the type of sensorineural hearing loss that standard hearing aids are designed to address. The research does not address conductive hearing loss or conditions requiring surgical intervention.

Are over-the-counter hearing aids as effective as prescription devices?
For adults with mild to moderate hearing loss, which is the population most represented in dementia-related hearing aid research, over-the-counter hearing aids have been shown to provide comparable benefit to prescription devices in multiple comparative studies. The FDA established the OTC hearing aid category in 2022 specifically for adults 18 and older with mild to moderate hearing loss. Adults with severe hearing loss, or those with medical conditions affecting their hearing, are typically better served by a prescription device fitted by a licensed audiologist.